# LAE118

Source: https://onco.cc/drugs/lae118/  
OnCo record `lae118` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LAE118 is an experimental pill from Laekna Therapeutics, in phase 1 trials for advanced solid tumours.

## Summary

LAE118 is a small molecule from Laekna Therapeutics. An allosteric PI3K-alpha inhibitor designed to act on the mutant forms of the enzyme (company poster title). The phase 1 study NCT07787520 tests it alone and with fulvestrant and palbociclib; the company says the first subject was enrolled in August 2026. Rights outside China were licensed to Vasque Bio in June 2026. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: LAE118
- Modality: Small molecule
- Mechanism: An allosteric PI3K-alpha inhibitor designed to act on the mutant forms of the enzyme (company poster title).

## Sources

- Laekna research and development: https://www.laekna.com/rd
- Laekna milestones: https://www.laekna.com/aboutus
- ClinicalTrials.gov NCT07787520: https://clinicaltrials.gov/study/NCT07787520

## Connected records

- targets: [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)
- trials: [A Study of LAE118 as Monotherapy and in Combination With Antitumor Agents in Advanced Solid Tumors](https://onco.cc/trials/nct07787520/)

---
JSON: https://onco.cc/api/v1/entities/lae118.json